POSEIDA THERAPEUTICS REPORTS POSITIVE INTERIM PHASE 1 RESULTS FOR ALLOGENEIC CAR-T THERAPY P-BCMA-ALLO1 WITH HIGH OVERALL RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS

Reuters · 09/27 20:30
POSEIDA THERAPEUTICS REPORTS POSITIVE INTERIM PHASE 1 RESULTS FOR ALLOGENEIC CAR-T THERAPY P-BCMA-ALLO1 WITH HIGH OVERALL RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS